Tafenoquine: First Global Approval
- 385 Downloads
Tafenoquine (Krintafel™, Arakoda™), an orally-active 8-aminoquinoline anti-malarial drug, is a long-acting analogue of primaquine with activity against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include Plasmodium vivax (P. vivax) and Plasmodium falciparum. It has been developed by GlaxoSmithKline (formerly SmithKline Beecham) for the radical cure of P. vivax malaria and by 60 Degrees Pharmaceuticals for the prophylaxis of malaria. The exact mechanism(s) of action underlying the anti-Plasmodium activity of tafenoquine are unknown, although it may exert its effect by inhibiting haematin polymerization and, additionally, by inducing mitochondrial dysfunction leading to the apoptotic-like death of the organism. In July 2018, tafenoquine was approved in the USA for the radical cure of P. vivax malaria in patients aged ≥ 16 years who are receiving appropriate antimalarial therapy for acute P. vivax malaria. Subsequently, in August 2018, tafenoquine was approved in the USA for the prophylaxis of malaria in patients aged ≥ 18 years. This article primarily summarizes the milestones in the development of tafenoquine leading to its first global approval for the radical cure of P. vivax malaria.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 4.Adis Insight. Drug profile: tafenoquine; 2018.Google Scholar
- 5.GlaxoSmithKline. KRINTAFEL (tafenoquine) tablets, for oral use: US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf. Accessed 9 Aug 2018.
- 6.Food and Drug Administration. NDA210795, NDA approval letter dated 07/20/2018. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210795Orig1s000Ltr.pdf. Accessed 9 Aug 2018.
- 7.Medicines for Malaria Venture, GlaxoSmithKline. US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria [media release]. 20 Jul 2018. http://www.gsk.com.
- 8.60 Degrees Pharmaceuticals. US Food and Drug Administration approves ARAKODA™ (tafenoquine) tablets for oral use; first preventative antimalarial approved in almost two decades [media release]. 9 Aug 2018. http://www.60degreespharma.com.
- 9.60 Degrees Pharmaceuticals LLC. ARAKODA™ (tafenoquine) tablets, for oral use: US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf. Accessed 9 Aug 2018.
- 10.GlaxoSmithKline. GSK submits regulatory application for single-dose tafenoquine for the treatment of Plasmodium vivax malaria to Australia’s Therapeutic Goods Administration [media release]. 15 Dec 2017. http://www.gsk.com.
- 11.60 Degrees Pharmaceuticals (60P) media center (Press). 28 Apr 2015. https://60degreespharma.com.
- 12.Knight. Knight takes right angle with 60 Degrees Pharmaceuticals LLC [media release]. 11 Dec 2015. http://www.gud-knight.com.
- 16.FDA. FDA briefing document: tafenoquine tablet, 150 mg_Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). 2018. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm612874.pdf. Accessed 9 Aug 2018.
- 20.Vennerstrom JL, Nuzum EO, Miller RE, et al. 8-Aminoquinoline derivatives against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother. 1999;42:598–602.Google Scholar
- 22.Waters NC, Edstein MD. 8-Aminoquinolines: primaquine and tafenoquine. In: Staines H, Krishna S, editors. Treatment and prevention of malaria: antimalarial drug chemistry, action and use. Basel: Springer; 2012. p. 69–94.Google Scholar
- 27.US National Institutes of Health. ClinicalTrials.gov identifier NCT01376167. 2018. https://clinicaltrials.gov. Accessed 10 Aug 2018.
- 28.US National Institutes of Health. ClinicalTrials.gov identifier NCT02216123. 2018. https://clinicaltrials.gov. Accessed 10 Aug 2018.
- 29.GlaxoSmithKline. Krintafel (tafenoquine succinate tablets) FDA Advisory Committee Briefing Document. 2018. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm612875.pdf. Accessed 9 Aug 2018.
- 37.US National Institutes of Health. ClinicalTrials.gov identifier NCT02658435. 2018. https://clinicaltrials.gov. Accessed 10 Aug 2018.
- 38.Data on file, GlaxoSmithKline. 2018.Google Scholar